Laboratory of Molecular CLL Pathogenesis

Univ.-Prof. Dr. Michael Hallek

Univ.-Prof. Dr. Michael Hallek

Leiter Labor für molekulare Pathogenese der CLL

CECAD Research Center, Gebäude 69

Publikationen (PubMed)

Zur Person

Kurzbiografie

Professor Hallek ist seit 2003 Direktor der Klinik I für Innere Medizin an der Uniklinik Köln.
Von 1978-1985 studierte er Medizin in Regensburg, München und Paris. Seine ärztliche Ausbildung erhielt er in München. Von 1990-1992 verbrachte er zwei Jahre als Postdoktorand am Dana-Farber-Cancer-Institute der Harvard Medical School in Boston.
Er ist Facharzt für Innere Medizin mit Schwerpunkt Hämatologie und internistische Onkologie.
Schwerpunkt seiner wissenschaftlichen Arbeit ist die Entwicklung spezifischer, molekularer Therapien für Leukämien. Er erhielt zahlreiche wissenschaftliche Auszeichnungen. Prof. Hallek ist Gründer und Leiter der Deutschen CLL-Studiengruppe (DCLLSG), der international führenden Studiengruppe zur Erforschung neuer Behandlungen der chronischen lymphatischen Leukämie.

Scientific Focus

Our laboratory is trying to identify novel genes which participate in the development of chronic lymphocytic leukemia. We focus on:

Analysis of the role of the tumor microenvironment for the development and promotion of chronic lymphocytic leukemia (CLL)

CLL is a malignant disease in which the survival of leukemic cells is strongly dependent of continuous stimulation by extracellular factors. We aim to explore this potential "Achilles heel" of CLL using a CLL mouse model and we work to develop novel therapeutic approaches in the future. By using gene knockout mice we analyze the role of cytokines/chemokines and of surface receptors in the development and promotion of CLL.

Target Validation

Here we identify candidate target molecules for the treatment of chronic lymphocytic leukemia (CLL) and other malignant diseases and validate them using animal models. We perform basic research on own molecules as well as on targets defined by others. For every gene, we design the optimal validation strategy and generate the appropriate animal models. This entails the generation of knockout and transgenic mice.

Genetic diagnostic of CLL risk

We work on the identification of small genetic differences between individuals, so called single nucleotide polymorphisms (SNPs), which may explain the great clinical variability of CLL disease. SNPs may help to predict the risk to develop CLL as well as to suffer of progressive disease once CLL is established.

Our long-term goal is to develop novel strategies for the treatment of CLL and other human malignancies. We want to pursue the targets in collaboration with industrial partners and test them in clinical trials.

The Team

Post-Doc
Dr. Nina Reinart
Dr. Oleg Fedorchenko
Dr. Hien Nguyen

MTLA
Natascha Rosen


Link zur deutschen Version

Nach oben scrollen